Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation
Open accessPublished version of a preprint
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Drug repurposing represents an attractive alternative to the costly and time-consuming process of new drug development, particularly for serious, widespread conditions with limited effective treatments, such as Alzheimer’s disease (AD). Emerging generative artificial intelligence (GAI) technologies like ChatGPT offer the promise of expediting the review and summary of scientific knowledge. To examine the feasibility of using GAI for identifying drug repurposing candidates, we iteratively tasked ChatGPT with proposing the twenty most promising drugs for repurposing in AD, and tested the top ten for risk of incident AD in exposed and unexposed individuals over age 65 in two large clinical datasets: (1) Vanderbilt University Medical Center and (2) the All of Us Research Program. Among the candidates suggested by ChatGPT, metformin, simvastatin, and losartan were associated with lower AD risk in meta-analysis. These findings suggest GAI technologies can assimilate scientific insights from an extensive Internet-based search space, helping to prioritize drug repurposing candidates and facilitate the treatment of diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A recent study employed GPT-4 to generate and prioritize potential AD therapeutics, followed by retrospective validation in two large-scale electronic health record cohorts from Vanderbilt University and the All of Us Research Program. Metformin, simvastatin, and losartan were each associated with reduced AD incidence after adjusting for confounders, highlighting the utility of generative models”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [360]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
MatchIt : Nonparametric Preprocessing for Parametric Causal Inference
Ho, D. E., Imai, K., King, G., & Stuart, E. A. (2011) · Journal of Statistical Software · doi:10.18637/jss.v042.i08 · Cited by 4,385 · cited 1×
“PS matching was performed using the MatchIt R package 36 .”
Kung, T. H., Cheatham, M., Medenilla, A., Sillos, C., De Leon, L., Elepaño, C., Madriaga, M., Aggabao, R., Diaz-Candido, G., Maningo, J., et al. (2023) · PLOS Digital Health · doi:10.1371/journal.pdig.0000198 · Cited by 4,115
Kung, T. H., Cheatham, M., ChatGPT, Medenilla, A., Sillos, C., De Leon, L., Elepaño, C., Madriaga, M., Aggabao, R., Diaz-Candido, G., et al. (2022) · doi:10.1101/2022.12.19.22283643 · Cited by 4,115
Large language models encode clinical knowledge
Singhal, K., Azizi, S., Tu, T., Mahdavi, S. S., Wei, J., Chung, H. W., Scales, N., Tanwani, A., Cole-Lewis, H., Pfohl, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06291-2 · Cited by 4,083 · cited 1×
“subsequent optimization of responses that display reasoning processes 4,5 .”
Large Language Models Encode Clinical Knowledge
Singhal, K., Azizi, S., Tu, T., Mahdavi, S. S., Wei, J., Chung, H. W., Scales, N., Tanwani, A., Cole-Lewis, H., Pfohl, S., et al. (2022) · arXiv · doi:10.48550/arxiv.2212.13138 · Cited by 4,083 · cited 1×
“subsequent optimization of responses that display reasoning processes 4,5 .”
Ayers, J. W., Poliak, A., Dredze, M., Leas, E. C., Zhu, Z., Kelley, J. B., Faix, D. J., Goodman, A. M., Longhurst, C. A., Hogarth, M., et al. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1838 · Cited by 2,613
The “All of Us” Research Program
The All of Us Research Program Investigators (2019) · New England Journal of Medicine · doi:10.1056/nejmsr1809937 · Cited by 2,440
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine
Lee, P., Bubeck, S., & Petro, J. (2023) · New England Journal of Medicine · doi:10.1056/nejmsr2214184 · Cited by 1,738 · cited 1×
“Beyondansweringgeneralquestions,GAIhasdemonstratedeffectivenessin specializedmedicalcontexts 6 , including answering U.S. Medical Licensing Examination questions 7 , clinical decision-making consultations 8 , and drug discovery 9 .”
MatchIt: Nonparametric Preprocessing for Parametric Causal Inference
Ho, D., Imai, K., King, G., Stuart, E., & Greifer, N. (2005) · CRAN: Contributed Packages · doi:10.32614/cran.package.matchit · Cited by 1,206
Matthews, K. A., Xu, W., Gaglioti, A. H., Holt, J. B., Croft, J. B., Mack, D., & McGuire, L. C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3063 · Cited by 1,124
The “All of Us” Research Program
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1912496 · Cited by 843
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
How is ChatGPT's behavior changing over time?
Chen, L., Zaharia, M., & Zou, J. (2023) · arXiv · doi:10.48550/arxiv.2307.09009 · Cited by 507 · cited 1×
“Lastly, the quality of LLM-generated responses for drug repurposing may vary over time 29 , in fl uenced by the continuous updates in data, learning techniques,andevaluatingmetricsinmodeltraining.”
Normalized names for clinical drugs: RxNorm at 6 years
Nelson, S. J., Zeng, K., Kilbourne, J., Powell, T., & Moore, R. (2011) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2011-000116 · Cited by 453
Using AI-generated suggestions from ChatGPT to optimize clinical decision support
Liu, S., Wright, A. P., Patterson, B. L., Wanderer, J. P., Turer, R. W., Nelson, S. D., McCoy, A. B., Sittig, D. F., & Wright, A. (2023) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocad072 · Cited by 397
OpenAI ChatGPT Generated Literature Review: Digital Twin in Healthcare
Aydın, Ö., & Karaarslan, E. (2022) · doi:10.2139/ssrn.4308687 · Cited by 391
Májovský, M., Černý, M., Kasal, M., Komarc, M., & Netuka, D. (2023) · Journal of Medical Internet Research · doi:10.2196/46924 · Cited by 301
Large language model (ChatGPT) as a support tool for breast tumor board
Sorin, V., Klang, E., Sklair-Levy, M., Cohen, I., Zippel, D. B., Balint Lahat, N., Konen, E., & Barash, Y. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00557-8 · Cited by 218 · cited 1×
“More-over, ChatGPT has shown promise as a clinical decision-support tool for offering patient management suggestions 11 .”
Exploring the Potential of Large Language Models (LLMs)in Learning on Graphs
Chen, Z., Mao, H., Li, H., Jin, W., Wen, H., Wei, X., Wang, S., Yin, D., Fan, W., Liu, H., et al. (2024) · ACM SIGKDD Explorations Newsletter · doi:10.1145/3655103.3655110 · Cited by 209 · cited 1×
“As research in this area evolves, it will be important for future investigations to focus on how best to leverage LLMs to discover novel insights in conjunction with explicit knowledge representation and reasoning technologies, such as knowledge graphs 30 .”
Decker, H., Trang, K., Ramirez, J., Colley, A., Pierce, L., Coleman, M., Bongiovanni, T., Melton, G. B., & Wick, E. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36997 · Cited by 178
Rapamycin and Alzheimer’s disease: Time for a clinical trial?
Kaeberlein, M., & Galvan, V. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aar4289 · Cited by 171
A conversation with ChatGPT on the role of computational systems biology in stem cell research
Cahan, P., & Treutlein, B. (2023) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.12.009 · Cited by 125
The Links between Cardiovascular Diseases and Alzheimer's Disease
Leszek, J., Вячеславовна, М. Е., Belousov, D. M., Koutsouraki, E., Szczechowiak, K., Kobusiak−Prokopowicz, M., Mysiak, A., Diniz, B. S., Somasundaram, S. G., Kirkland, C. E., et al. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200729093724 · Cited by 115 · cited 1×
“Similarly, reported associations between AD and cardiovascular disease have sparked numerous investigations into the repurposing of cardiovascular drugs for AD, including statins and anti-hypertensive agents such as losartan and candesartan 18 – 20 .”
Assessing Missing Data Assumptions in EHR-Based Studies: A Complex and Underappreciated Task
Haneuse, S., Arterburn, D., & Daniels, M. J. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0184 · Cited by 110
Cerebrovascular insulin receptors are defective in Alzheimer’s disease
Leclerc, M., Bourassa, P., Tremblay, C., Caron, V., Sugère, C., Emond, V., Bennett, D. A., & Calon, F. (2023) · Brain · doi:10.1093/brain/awac309 · Cited by 108
Development and evaluation of an ensemble resource linking medications to their indications
Wei, W.-Q., Cronin, R. M., Xu, H., Lasko, T. A., Bastarache, L., & Denny, J. C. (2013) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2012-001431 · Cited by 106
Self-citationEvaluating the logical reasoning ability of chatgpt and GPT-4
Liu, H., Ning, R., Teng, Z., Liu, J., Zhou, Q., & Zhang, Y. (2023) · arXiv · doi:10.48550/arxiv.2304.03439 · Cited by 100 · cited 1×
“subsequent optimization of responses that display reasoning processes 4,5 .”
Assessing the Value of ChatGPT for Clinical Decision Support Optimization
Liu, S., Wright, A. P., Patterson, B. L., Wanderer, J. P., Turer, R. W., Nelson, S. D., McCoy, A. B., Sittig, D. F., & Wright, A. (2023) · doi:10.1101/2023.02.21.23286254 · Cited by 90
Drug discovery companies are customizing ChatGPT: here’s how
Savage, N. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01788-7 · Cited by 86 · cited 1×
“Additionally, ChatGPT is already being leveraged by biotechnology companies to suggest novel pathways for drug targets 12 .”
Chakraborty, C., Bhattacharya, M., & Lee, S.-S. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.08.009 · Cited by 81
Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseases
Torrandell‐Haro, G., Branigan, G. L., Vitali, F., Geifman, N., Zissimopoulos, J. M., & Brinton, R. D. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12108 · Cited by 79
Antidiabetic Drugs in the Treatment of Alzheimer’s Disease
Michailidis, M., Tata, D. A., Moraitou, D., Kavvadas, D., Karachrysafi, S., Papamitsou, T., Vareltzis, P., & Papaliagkas, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094641 · Cited by 69
The Links between Cardiovascular Diseases and Alzheimer's Disease
Leszek, J. (2021) · Current Neuropharmacology · doi:10.2174/18756190mta4dnje52 · Cited by 69
Ha, J.-H., Choi, D., Kim, K. J., Cho, S. Y., Kim, H., Kim, K. Y., Koh, Y., Nam, C. M., & Kim, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-03406-5 · Cited by 68 · cited 1×
“Despite supporting fi ndings for these three drugs in previous studies, much remains unknown about the mechanisms by which these drugs affect AD pathophysiology and pathology, and population-based studies have not provided conclusive results 24 – 26 .”
The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence
Tousi, B. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s61309 · Cited by 65
Kehoe, P. G., Turner, N. L., Howden, B., Jarutytė, L., Clegg, S., Malone, I. B., Barnes, J., Nielsen, C. F., Sudre, C. H., Wilson, A., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00263-5 · Cited by 62
Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257700 · Cited by 55
Self-citationAssociation between statin use and Alzheimer’s disease with dose response relationship
Jeong, S., Shin, D. W., Yoo, T. G., Cho, M. H., Jang, W., Lee, J., & Kim, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-94803-3 · Cited by 40
Adesuyan, M., Jani, Y. H., Alsugeir, D. M., Cheung, E. C. L., Chui, C. S. L., Howard, R. J., Wong, I. C. K., & Brauer, R. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.77 · Cited by 37 · cited 1×
“Similarly, reported associations between AD and cardiovascular disease have sparked numerous investigations into the repurposing of cardiovascular drugs for AD, including statins and anti-hypertensive agents such as losartan and candesartan 18 – 20 .”
Zheng, N. S., Warner, J. L., Osterman, T. J., Wells, Q. S., Shu, X., Deppen, S. A., Karp, S. J., Dwyer, S., Feng, Q., Cox, N. J., et al. (2020) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2020.103657 · Cited by 28 · cited 1×
“VUMC ’ s de-identi fi ed EHR database contains longitudinal clinical data including diagnosis codes, lab values, and medications for over three million patient records 31 .”
Self-citationNilotinib: from animal-based studies to clinical investigation in Alzheimer’s disease patients
Nobili, A., D’Amelio, M., & Viscomi, M. T. (2022) · Neural Regeneration Research · doi:10.4103/5374.350700 · Cited by 21
Exploring the Potential of Large Language Models (LLMs) in Learning on GraphsPreprint
Chen, Z., Mao, H., Li, H., et al. (2023) · arXiv (Cornell University) · doi:10.48550/arxiv.2307.03393 · Cited by 20 · cited 1×
“As research in this area evolves, it will be important for future investigations to focus on how best to leverage LLMs to discover novel insights in conjunction with explicit knowledge representation and reasoning technologies, such as knowledge graphs 30 .”
Thakkar, R., Liu, G., Zhao, J., Ong, H. H., Li, B., Wen, Z., & Wei, W. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.065899 · Cited by 3
Self-citation
Cited by
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Scherbakov, D., Hubig, N., Jansari, V., Bakumenko, A., & Lenert, L. A. (2024) · arXiv · doi:10.48550/arxiv.2409.04600 · Cited by 156
Scherbakov, D., Hubig, N., Jansari, V., Bakumenko, A., & Lenert, L. A. (2025) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaf063 · Cited by 154
Applications of Artificial Intelligence in Drug Repurposing
Wan, Z., Sun, X., Li, Y., Chu, T., Hao, X., Cao, Y., & Zhang, P. (2025) · Advanced Science · doi:10.1002/advs.202411325 · Cited by 127
Ng, K. K. Y., Matsuba, I., & Zhang, P. C. (2025) · NEJM AI · doi:10.1056/aira2400380 · Cited by 107
Metadata
- Authors
- Yan, C., Grabowska, M. E., Dickson, A. L., Li, B., Wen, Z., Roden, D. M., Michael Stein, C., Embí, P. J., Peterson, J. F., Feng, Q., Malin, B. A., & Wei, W.-Q.
- Affiliations
- Vanderbilt University Medical Center (US)
- Vanderbilt University (US)
- Emory University (US)
- Corresponding author
- Wei, Wei-Qi
- ORCID
- Venue
- npj Digital Medicine
- Published
- 2024-02-26
- Volume
- 7
- Issue
- 1
- Pages
- 46-46
- ISSN
- 2398-6352 (ISSN-L)
- PMC
- PMC10897392
- OpenAlex
- W4392162026
- Cited by
- 73
- References
- 40
- Citations by year
- 2026: 23 · 2025: 37 · 2024: 13
- FWCI
- 20.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- npj Digital Medicine (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (R01AG069900, F30AG080885)
- U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM139891, R35GM131770)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- drug repurposing, Alzheimer's disease, generative AI, ChatGPT, candidate prioritization, metformin, simvastatin, losartan, older adults, real-world clinical data, All of Us
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.